<DOC>
	<DOCNO>NCT00897065</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict well patient respond treatment . PURPOSE : This laboratory study look biomarkers may predict response tamoxifen letrozole postmenopausal woman primary breast cancer treat clinical trial CAN-NCIC-MA17 .</brief_summary>
	<brief_title>Biomarkers Predicting Response Tamoxifen Letrozole Postmenopausal Women With Primary Breast Cancer Treated Clinical Trial CAN-NCIC-MA17</brief_title>
	<detailed_description>OBJECTIVES : - Assess prognostic utility MGH 2-gene GHI 21-gene expression signature postmenopausal woman primary breast cancer treat tamoxifen follow either placebo letrozole clinical trial CAN-NCIC-MA17 . - Assess ability MGH 2-gene GHI 21-gene expression signature predict responsiveness letrozole . - Compare prognostic utility quantitative immunofluorescence v standard immunohistochemistry estrogen receptor , progesterone receptor , HER-2 , tumor aromatase , cyclooxygenase-2 , GATA-3 , NAT-1 patient . - Assess ability quantitative immunofluorescence standard immunohistochemistry proteins predict responsiveness letrozole patient . - Use gene discovery formalin-fixed , paraffin-embedded tumor specimen identify novel gene expression profile may predict outcome responsiveness letrozole patient . OUTLINE : This control study . Formalin-fixed , paraffin-embedded breast tumor tissue sample analyze MGH 2-gene GHI 21-gene expression signature use real-time quantitative polymerase chain reaction . Immunohistochemistry immunofluorescence use analysis estrogen receptor , progesterone receptor , HER-1 -2 , aromatase , GATA-3 , NAT-1 , cyclooxygenase-2 . Microarray hybridization use identify novel gene expression signature . PROJECTED ACCRUAL : A total 957 specimen accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary invasive breast carcinoma resect time original diagnosis Treated clinical trial CANNCICMA17 Hormone receptor status : Estrogen progesterone receptor positive tumor PATIENT CHARACTERISTICS : Female Postmenopausal PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
</DOC>